Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mamiko Kuroiwa
Observed names:
M. Kuroiwa,
黒岩真美子
Institution:
Hyogo Medical University
Observed institution:
Hyogo Medical University
ORCID:
0009-0005-9049-6808
Observed ORCID:
0009-0005-9049-6808
OpenAlex ID:
A5113005174
The cytokine profile correlates with less tumor-infiltrating lymphocytes in luminal A breast cancer
2024
·
Eri Ishikawa
, Takahiro Watanabe
, et al.
·
Breast Cancer Research and Treatment
·
6
PDF
An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia
2025
·
Masayuki Nagahashi
, Miki Komatsu
, et al.
·
Cancer Research Communications
·
5
Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin
2023
·
Ayako Bun
, Masayuki Nagahashi
, et al.
·
Breast Cancer Research and Treatment
·
5
PDF
Targeting Interleukin‐6 as a Novel Strategy to Overcome Eribulin Resistance in Breast Cancer
2025
·
Akira Hattori
, Masayuki Nagahashi
, et al.
·
Cancer Medicine
·
2
PDF
Prognostic significance of peripheral myeloid-derived suppressor cells in advanced breast cancer
2026
·
Haruka Kanaoka
, Masayuki Nagahashi
, et al.
·
Breast Cancer
PDF
Abstract PS4-01-24: Cytokine score based on expression levels of multiple cytokines is a prognostic indicator in metastatic breast cancer patients treated with chemotherapy
2026
·
J. Tsuchida
, M. Nagahashi
, et al.
·
Clinical Cancer Research
Data from An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia
2025
·
Masayuki Nagahashi
, Miki Komatsu
, et al.
Figure 4 from An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia
2025
·
Masayuki Nagahashi
, Miki Komatsu
, et al.
Figure 5 from An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia
2025
·
Masayuki Nagahashi
, Miki Komatsu
, et al.
Figure 3 from An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia
2025
·
Masayuki Nagahashi
, Miki Komatsu
, et al.
Figure 2 from An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia
2025
·
Masayuki Nagahashi
, Miki Komatsu
, et al.
Figure 1 from An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia
2025
·
Masayuki Nagahashi
, Miki Komatsu
, et al.
Supplementary Figure 1 from An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia
2025
·
Masayuki Nagahashi
, Miki Komatsu
, et al.
Abstract P4-05-28: The cytokine profile correlates with less tumor-infiltrating lymphocytes in luminal A breast cancer
2025
·
Aoi Oshiro
, Eri Ishikawa
, et al.
·
Clinical Cancer Research
Abstract P4-12-26: Preclinical study of newly developed anti-breast cancer drug targeting sphingosine-1-phosphate utilizing a novel drug delivery system
2025
·
Masayuki Nagahashi
, Sayaka Urano
, et al.
·
Clinical Cancer Research
Abstract PO2-15-09: Immune related cell fraction in peripheral blood and outcomes of advanced breast cancer patients treated with Eribulin
2024
·
Masayuki Nagahashi
, Ayako Bun
, et al.
·
Cancer Research
Show more works
View as search
Works count:
17
Citation count:
18
H-index:
3
I10-index:
Year
Topic
Type